

FILE 'HOME' ENTERED AT 13:48:01 ON 02 MAY 2007

=> ile reg

ILE IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:48:08 ON 02 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 MAY 2007 HIGHEST RN 934050-43-8

DICTIONARY FILE UPDATES: 1 MAY 2007 HIGHEST RN 934050-43-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>  
Uploading C:\Program Files\Stnexp\Queries\xanthine.str

L1 STRUCTURE UPLOADED

=> s l1 fam sam

SAMPLE SEARCH INITIATED 13:49:10 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 1 TO 80  
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA FAM SAM L1

=> s l1 fam full

FULL SEARCH INITIATED 13:49:20 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 58 TO ITERATE


100.0% PROCESSED 58 ITERATIONS 12 ANSWERS  
SEARCH TIME: 00.00.01

L3 12 SEA FAM FUL L1

=> d scan

L3 12 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 1H-Purine-2,6-dione, 8-[(1E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-  
3,7-dihydro-7-methyl-, hexahydrate (9CI)  
MF C20 H24 N4 O4 . 6 H2 O

Double bond geometry as shown.



● 6 H<sub>2</sub>O

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):

FILE 'CAPLUS' ENTERED AT 13:49:38 ON 02 MAY 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 May 2007 VOL 146 ISS 19  
FILE LAST UPDATED: 1 May 2007 (20070501/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13

L4 83 L3

=> s anxiety  
16873 ANXIETY  
48 ANXIETIES  
L5 16908 ANXIETY  
(ANXIETY OR ANXIETIES)

=> s anxiet? or anxio?  
16912 ANXIET?  
13439 ANXIO?  
L6 22647 ANXIET? OR ANXIO?

=> s 14 and 16  
L7 1 L4 AND L6

=> d ti au abs so py

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN  
TI A method using an adenosine A2A receptor antagonist for treating an anxiety disorder  
IN Kase, Hiroshi; Seno, Naoki; Shiozaki, Shizuo; Kobayashi, Minoru; Kase, Junya  
AB Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist (e.g. a xanthine derivative) to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A2A receptor antagonist.  
SO PCT Int. Appl., 96 pp.  
CODEN: PIXXD2  
PY 2004  
2004  
2004  
2006  
2006  
2006  
2006  
2006  
2005

=> s phob? or stress  
2354 PHOB?  
531845 STRESS  
95856 STRESSES  
570322 STRESS  
(STRESS OR STRESSES)  
L8 572256 PHOB? OR STRESS

=> s 14 and 18  
L9 1 L4 AND L8

=> d ti au abs so py 1-10 14

L4 ANSWER 1 OF 83 CAPLUS COPYRIGHT 2007 ACS on STN  
TI Compositions and methods for inhibiting neurodegeneration  
IN Kalb, Robert Gordon; Mojsilovic-Petrovic, Jelena  
AB Methods effective for inhibiting neuronal degeneration, particularly in amyotrophic lateral sclerosis (ALS) patients are disclosed. Also provided are screening assays for identifying such agents.  
SO U.S. Pat. Appl. Publ., 36pp.  
CODEN: USXXCO  
PY 2007

L4 ANSWER 2 OF 83 CAPLUS COPYRIGHT 2007 ACS on STN  
TI Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice  
AU Xiao, Danqing; Bastia, Elena; Xu, Yue-Hang; Benn, Caroline L.; Cha, Jang-Ho J.; Peterson, Tracy S.; Chen, Jiang-Fan; Schwarzschild, Michael A.  
AB Adenosine A2A receptor antagonists provide a promising nondopaminergic approach to the treatment of Parkinson's disease (PD). Initial clin. trials of A2A antagonists targeted PD patients who had already developed treatment complications known as L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID) in an effort to improve symptoms while reducing existing LID. The goal of this study is to explore the effect of A2A antagonists and targeted A2A receptor depletion on the actual development of sensitized responses to L-DOPA in mouse models of LID in PD. Hemiparkinsonian mice (unilaterally lesioned with 6-OHDA) were treated daily for 3 wk with a low dose of L-DOPA (2 mg/kg) preceded by a low dose of selective A2A antagonist (KW-6002 [(E)-1,3-diethyl-8-(3,4-dimethoxystyryl)-7-methyl-3,7-dihydro-1H-purine-2,6-dione] at 0.03 or 0.3 mg/kg, or SCH58261 [5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine] at 0.03 mg/kg) or vehicle i.p. In control mice, contralateral rotational responses to daily L-DOPA gradually increased over the initial week before reaching a persistent maximum. Both A2A antagonists inhibited the development of sensitized contralateral turning, with KW-6002 pretreatment reducing the sensitized rotational responses by up to threefold. The development of abnormal involuntary movements (a measure of LID) as well as rotational responses was attenuated by the postnatal depletion of forebrain A2A receptors in conditional (Cre/loxP system) knock-out mice. These pharmacol. and genetic data provide evidence that striatal A2A receptors play an important role in the neuro-plasticity underlying behavioral sensitization to L-DOPA, supporting consideration of early adjunctive therapy with an A2A antagonist to reduce the risk of LID in PD.  
SO Journal of Neuroscience (2006), 26(52), 13548-13555  
CODEN: JNRSDS; ISSN: 0270-6474  
PY 2006

L4 ANSWER 3 OF 83 CAPLUS COPYRIGHT 2007 ACS on STN  
TI Identification of non-furan containing A2A antagonists using database mining and molecular similarity approaches  
AU Richardson, Christine M.; Gillespie, Roger J.; Williamson, Douglas S.; Jordan, Allan M.; Fink, Alexandra; Knight, Antony R.; Sellwood, Daniel M.; Misra, Anil  
AB Database searching led to the identification of potent A2A antagonists which do not contain the privileged furan moiety and which show selectivity over A1 receptors. Simple substructure searching on a proprietary database identified compds. with activities in the low nM range. A targeted approach to the identification of non-furan containing compds. resulted in the identification of two novel series, with potency, selectivity and directional SAR from screening 113 compds.  
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(23), 5993-5997  
CODEN: BMCLE8; ISSN: 0960-894X  
PY 2006

L4 ANSWER 4 OF 83 CAPLUS COPYRIGHT 2007 ACS on STN  
TI Novel neuroprotection by caffeine and adenosine A2A receptor antagonists in animal models of Parkinson's disease  
AU Kalda, Anti; Yu, Liqun; Oztas, Emin; Chen, Jiang-Fan  
AB A review. The adenosine A2A receptor has recently emerged as a leading non-dopaminergic therapeutic target for Parkinson's disease, largely due to the restricted distribution of the receptor in the striatum and the profound interaction between adenosine and dopamine receptors in brain. Two lines of research in particular have demonstrated the promise of the A2A receptor antagonists as novel anti-parkinsonian drugs. First, building on extensive preclin. animal studies, the A2A receptor antagonist

KW6002 has demonstrated its potential to increase motor activity in PD patients of the advanced stage in a recent clin. phase IIB trial. Second, recently two prospective epidemiol. studies of large cohorts have firmly established the inverse relationship between the consumption of caffeine (a non-specific adenosine antagonist) and the risk of developing PD. The potential neuroprotective effect of caffeine and A2A receptor antagonists in PD is further substantiated by the demonstration that pharmacol. blockade (by caffeine or specific A2A antagonists) or genetic depletion of the A2A receptor attenuated dopaminergic neurotoxicity and neurodegeneration in animal models of PD. Moreover, A2A receptor antagonism-mediated neuroprotection goes beyond PD models and can be extended to a variety of other brain injuries induced by stroke, excitotoxicity and mitochondrial toxins. Intensive investigations are under way to dissect out common cellular mechanisms (such as A2A receptor modulation of neuroinflammation) which may underlie the broad spectrum of neuroprotection by A2A receptor inactivation in brain.

SO Journal of the Neurological Sciences (2006), 248(1-2), 9-15  
CODEN: JNSCAG; ISSN: 0022-510X  
PY 2006

L4 ANSWER 5 OF 83 CAPLUS COPYRIGHT 2007 ACS on STN  
TI Protecting motor neurons from toxic insult by antagonism of adenosine A2a and Trk receptors. [Erratum to document cited in CA145:411022]  
AU Mojsilovic-Petrovic, Jelena; Jeong, Goo-Bo; Crocker, Amanda; Arneja, Amrita; David, Samuel; Russell, David S.; Kalb, Robert G.  
AB The name of the sixth author, David S. Russell, was given incorrectly as "David Russell".  
SO Journal of Neuroscience (2006), 26(40), No pp. given  
CODEN: JNRSDS; ISSN: 0270-6474  
PY 2006

L4 ANSWER 6 OF 83 CAPLUS COPYRIGHT 2007 ACS on STN  
TI Protecting motor neurons from toxic insult by antagonism of adenosine A2a and Trk receptors  
AU Mojsilovic-Petrovic, Jelena; Jeong, Goo-Bo; Crocker, Amanda; Arneja, Amrita; David, Samuel; Russell, David; Kalb, Robert G.  
AB The death of motor neurons in amyotrophic lateral sclerosis (ALS) is thought to result from the interaction of a variety of factors including excitotoxicity, accumulation of toxic proteins, and abnormal axonal transport. Previously, we found that the susceptibility of motor neurons to excitotoxic insults can be limited by inhibiting signals evoked by brain-derived neurotrophic factor (BDNF) activation of the receptor tyrosine kinase B (TrkB). Here we show that this can be achieved by direct kinase inhibition or by blockade of a transactivation pathway that uses adenosine A2a receptors and src-family kinases (SFKs). Downstream signaling cascades (such as mitogen-activated protein kinase and phosphatidylinositol-3 kinase) are inhibited by these blockers. In addition to protecting motor neurons from excitotoxic insult, these agents also prevent toxicity that follows from the expression of mutant proteins (G85R superoxide dismutase 1; G59S p150glued) that cause familial motor neuron disease. TrkB, adenosine A2a receptors, and SFKs associate into complexes in lipid raft and nonlipid raft membranes and the signaling from lipids rafts may be particularly important because their disruption by cholesterol depletion blocks the ability of BDNF to render motor neurons vulnerable to insult. The neuroprotective versatility of Trk antagonism suggests that it may have broad utility in the treatment of ALS patients.  
SO Journal of Neuroscience (2006), 26(36), 9250-9263  
CODEN: JNRSDS; ISSN: 0270-6474  
PY 2006

L4 ANSWER 7 OF 83 CAPLUS COPYRIGHT 2007 ACS on STN  
TI Assay development and screening of a serine/threonine kinase in an on-chip mode using caliper nanofluidics technology  
AU Perrin, Dominique; Fremaux, Christele; Scheer, Alexander

AB Kinases are key targets for drug discovery. In the field of screening in general and especially in the kinase area, because of considerations of efficiency and cost, radioactivity-based assays tend to be replaced by alternative, mostly fluorescence-based, assays. Today, the limiting factor is rarely the number of data points that can be obtained but rather the quality of the data, enzyme availability, and cost. In this article, the authors describe the development of an assay for a kinase screen based on the electrophoretic separation of fluorescent product and substrate using a Caliper-based nanofluidics environment in on-chip incubation mode. The authors present the results of screening a focused set of 32,000 compds. together with confirmation data obtained in a filtration assay. In addition, they have made a small-scale comparison between the on-chip and off-chip nanofluidics screening modes. In their hands, the screen in on-chip mode is characterized by high precision most likely due to the absence of liquid pipetting; an excellent confirmation rate (62%) in an independent assay format, namely, filtration; and good sensitivity. This study led to the identification of 4 novel chemical series of inhibitors.

SO Journal of Biomolecular Screening (2006), 11(4), 359-368

CODEN: JBISF3; ISSN: 1087-0571

PY 2006

L4 ANSWER 8 OF 83 CAPLUS COPYRIGHT 2007 ACS on STN

TI Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders

IN Grzelak, Michael; Hunter, John; Pond, Annamarie; Varty, Geoffrey

AB A method for the treatment or prevention of extra pyramidal syndrome (EPS), dystonia, restless legs syndrome (RLS) or periodic leg movement in sleep (PLMS) comprising the administration of an adenosine A2a receptor antagonist, alone or in combination with other agents is described. Pharmaceutical compns. consisting of an adenosine A2a receptor antagonist in combination with an antipsychotic agent, an anticonvulsant agent, lithium or an opioid are also provided. Thus, monkeys, previously sensitized to the chronic effects of haloperidol, that exhibited EPS when administered haloperidol acutely, were used in a crossover, balanced design study to evaluate adenosine A2a receptor antagonist administered orally, in conjunction with haloperidol. The adenosine A2a receptor antagonist studied prevented the onset of EPS and delayed the onset of EPS by an average of 2.3 to 2.9 h.

SO U.S. Pat. Appl. Publ., 28 pp., Cont.-in-part of U.S. Ser. No. 234,644.

CODEN: USXXCO


PY 2006  
2004  
2005  
2005  
2005  
2005  
2006  
2006  
2007

L4 ANSWER 9 OF 83 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preventive and/or therapeutic agent for drug dependence

IN Kase, Junya; Kurokawa, Masako; Shiozaki, Shizuo; Seno, Naoki

GI



AB A preventive and/or therapeutic agent for drug dependence which contains as an active ingredient either a compound having antagonistic activity against an adenosine A<sub>2A</sub> receptor, such as a xanthine derivative represented by, e.g., the formula (I) (wherein R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> are the same or different and each represents hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; R<sub>4</sub> represents cycloalkyl, -(CH<sub>2</sub>)<sub>n</sub>-R<sub>5</sub>, or the -C(Y<sub>1</sub>):C(Y<sub>2</sub>)Z; and X<sub>1</sub> and X<sub>2</sub> are the same or different and each represents oxygen or sulfur) or a pharmacol. acceptable salt of the compound

SO PCT Int. Appl., 46 pp.

CODEN: PIXXD2

PY 2006

L4 ANSWER 10 OF 83 CAPLUS COPYRIGHT 2007 ACS on STN

TI Adenosine A<sub>2a</sub> receptor antagonists for the treatment of extrapyramidal syndrome and other movement disorders

IN Grzelak, Michael; Hunter, John; Pond, Annamarie; Varty, Geoffrey

AB The invention discloses a method for the treatment or prevention of extrapyramidal syndrome (EPS), dystonia, restless legs syndrome (RLS) or periodic leg movement in sleep (PLMS), comprising the administration of an adenosine A<sub>2a</sub> receptor antagonist, alone or in combination with other agents useful for treating EPS, dystonia, RLS or PLMS.

SO U.S. Pat. Appl. Publ., 27 pp., Cont.-in-part of U.S. Ser. No. 738,906.

CODEN: USXXCO

PY 2006

2004

2005

2005

2005

2005

2006

2006

2007

=>